QDENGA Dengue Vaccine: India’s First Approved Dengue Vaccine

India set to get its first approved dengue vaccine with QDENGA to be marketed in the private sector in the first six months of 2027. The vaccine, which has been developed by the Japanese drug manufacturing company, Takeda, has received marketing authorisation from the Indian Central Drugs Standard Control Organisation (CDSCO) in July 2026 for use among people aged between 4 and 60 years.

The development has increased the ways of dengue prevention, including controlling mosquitoes and minimizing exposure to Aedes mosquitoes.

What Is QDENGA?

QDENGA, also referred to as TAK-003, is a live attenuated tetravalent dengue vaccine.

It is intended to provide protection from the four types of the virus,

• DENV-1
• DENV-2
• DENV-3
• DENV-4

In 2024, WHO provided prequalification to QDENGA. It is given in two doses, three months apart.

According to the approved indication, it is not necessary to carry out tests on dengue infection before administering the vaccine.

Who Can Receive QDENGA in India?

In India, QDENGA has been licensed by CDSCO for use among the individuals aged 4-60 years.

But just because of such a license, this doesn’t mean all individuals aged between 4 and 60 would be able to get the vaccine. QDENGA will first become available in the private sector, and its price has not yet been disclosed.

Healthcare professionals can decide whether vaccination is necessary for the person.

Comparing QDENGA and DengiAll

India is developing its own dengue vaccine called DengiAll, and currently, these vaccines are regulated differently.

Features	QDENGA	DengiAll
Developer	Takeda	Developed in India
Other name	TAK-003	DengiAll
Vaccine type	Tetravalent	Tetravalent
Status in India	CDSCO-licensed	Undergoing large-scale clinical trials
Age range of the individuals that can be vaccinated	4-60 years old	Not yet approved
Number of doses	2 doses (3 months apart)	The schedule is under evaluation
Status according to WHO	Prequalified in 2024	Pending

DengiAll is undergoing large-scale clinical trials, and at the moment it cannot be considered an approved vaccine in India.

When Will QDENGA Be Made Available in India?

It is expected that QDENGA will be made available in India’s private market by the mid-2027, it also provided that all the local regulatory and commercial procedures have been completed successfully.

Takeda has reached an agreement with Dr Reddy’s Laboratories regarding the distribution of QDENGA in the private paediatric and adult market in India.

The cost and any future availability through public immunization programs have yet to be revealed.

Why Is QDENGA Significant?

Dengue is mainly spread through infected Aedes mosquitoes and may lead to symptoms like fever, body pain, and even severe dengue.

Vaccination would act as another prevention technique along with controlling of mosquitoes, removal of breeding sites, and protection from mosquito bites.

The significance of QDENGA in India’s case is that it brings in a licensed vaccine for dengue to India’s prevention picture. The extent of its significance would depend upon various aspects such as pricing, availability, and others.